YOu've changed your sentiment sharply. Its understandable, its been a long and miserable ride in most bio-techs in the last two years, rising less than the rest of the market on the Fed bubble and falling more than the general mkt since.
2022 could be a very different year:
https://www.fiercebiotech.com/biotech/biopharma-ma-2022-different-animal-drugmakers-coffers-lined-17t
If OCC does not get some partnerships going I'd be very surprised in that context. I expect continued M&A in the CAR-T cell space, but plenty of spill over...
YOu've changed your sentiment sharply. Its understandable, its...
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
46.0¢ |
Change
0.005(1.10%) |
Mkt cap ! $96.40M | |||
| Open | High | Low | Value | Volume |
| 45.5¢ | 46.5¢ | 45.5¢ | $87.13K | 189.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 271 | 46.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 46.5¢ | 21507 | 1 |
View Market Depth
| Last trade - 15.40pm 04/10/2024 (20 minute delay) ? |
| OCC (ASX) Chart |